Adherence to a healthier, anti-inflammatory diet was associated with a reduced risk for all-cause mortality among patients with RA.

Better cardiovascular safety and lower risk of all-cause mortality was observed among older adult patients with IBD who received ustekinumab vs vedolizumab.

Pediatric patients who adopted and sustained a CD exclusion diet achieved clinical remission and reported improvement in clinical symptoms and fecal calprotectin.

Certain metabolic factors are associated with the development of chronic musculoskeletal pain, including higher BMI and the presence of diabetes.

Contemporary estrogen-progestin contraceptives are associated with an increased risk for ischemic stroke and myocardial infarction.

A recent study finds that women with epilepsy may have offspring with decreased bone metabolism and lower birth weight.

The US FDA has approved a new drug application for a tablet version of Evrysdi (risdiplam) for people living with spinal muscular atrophy.

The use of combined oral contraceptives may delay the onset of hidradenitis suppurativa among women and may improve disease severity.

In the United States, SLE treatment trends between 2007 and 2023 show a continued reliance on glucocorticoids, despite advances in steroid-sparing agents.

Patients with CLE who have specific patient characteristics may have lower treatment response than patients who do not have these characteristics.

Results of a database review revealed duloxetine, pregabalin, and milnacipran as the only effective pharmacological therapies for managing pain in fibromyalgia.

The FDA has granted Fast Track designation to PP-01 for the mitigation of cannabis withdrawal symptoms in patients with cannabis use disorder.